Skip to main content
PepStack
Wiki · Profile

Sermorelin

GHRH(1-29) · GRF 1-29

GH SecretagoguePreclinical
From$5.50/mgCompare prices
MW
3357.9g/mol
Formula
C149H246N44O42S

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), primarily derived from the first 29 amino acids of the natural hormone, and classified as a growth hormone secretagogue. Researchers primarily study it for its potential role in stimulating endogenous growth hormone production and its implications in conditions such as hypogonadism and metabolic syndrome. Key findings from the literature indicate that sermorelin can activate insulin-like growth factor 1 (IGF-1) signaling pathways and may improve body composition by reducing fat mass and enhancing muscle growth. Additionally, studies have highlighted its influence on cellular signaling networks involved in tissue regeneration and recovery from injuries. Current research status reveals a need for further clinical trials to better understand its efficacy and safety in diverse populations.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC149H246N44O42S
Molecular Weight3357.9 g/mol
CAS Number86168-78-7
PubChem CID16132413

Half-Life

SCSubcutaneous

Data limited

IMIntramuscular

Data limited

IVIntravenous

~10 to 20 minutes

INIntranasal

Not applicable

POOral

Poor bioavailability

Due to its peptide nature, Sermorelin is rapidly degraded in the gastrointestinal tract, limiting its oral bioavailability.

Mechanism

Mechanism of Action

Sermorelin acts as a growth hormone-releasing hormone (GHRH) analog, binding to GHRH receptors on pituitary cells, which stimulates the release of endogenous growth hormone (GH). This, in turn, activates the insulin-like growth factor 1 (IGF-1) signaling pathway, promoting anabolic processes such as protein synthesis, tissue growth, and regeneration, while also influencing metabolic pathways like the PI3K/Akt and mTOR pathways. Although the exact mechanisms and downstream effects are still being elucidated, its role in enhancing body composition and metabolic health is well-documented.

Research

8 Research Publications

211

Total Citations

6

Human/RCT

1.0

Avg. Influence

2023

Latest

Sort
Filter
#01

PEGylation of growth hormone-releasing hormone (GRF) analogues.

Esposito P, et al. · Advanced drug delivery reviews · 2003

AnimalInfluence1.0
71
The study demonstrated that PEGylation of sermorelin can enhance its stability and pharmacodynamic response, potentially improving its therapeutic utility.

Key findings

  1. 01Researchers observed that PEGylation improved the stability and half-life of GRF in the body.
  2. 02The study found that different PEGylated GRF variants showed varying levels of biological activity.
  3. 03Mono-PEGylated versions of GRF demonstrated similar or greater effectiveness in stimulating growth hormone release compared to the unmodified version.
PubMed
#02

Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH.

Case Report
70
The study demonstrated that administration of sermorelin did not significantly affect fetal hGH secretion, while it elicited a small rise in maternal hGH serum concentrations in pregnant women.
PubMed
#03

Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe.

Review
28
The study demonstrated that very few falsified biopharmaceutical injectables, including sermorelin, were reported among the 21,000 seized dose units of falsified antibiotics in Europe during Operation Resistance.
0.1 mg/kgi.v.(rat)0.3 mg/kgi.v.(rat)1 mg/kgi.v.(rat)0.1 microgwithin the paraventricular nucleus of the hypothalamus(rat)1 microgwithin the paraventricular nucleus of the hypothalamus(rat)6 mgsubcutaneously(human)0.01 mg/kgsubcutaneous(human)2 consecutive weeks0.025 mg/kgsubcutaneous(human)20 microg kg(-1) per 48 hs.c.(rat)48 hours2 mg/kgintraperitoneal(rat)3 mg/kgintraperitoneal(rat)
PubMed
#04

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

Prakash A & Goa K L · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999

Human
18
The study demonstrated that sermorelin effectively stimulates growth hormone secretion in children with idiopathic growth hormone deficiency, leading to sustained increases in height velocity during treatment.

Key findings

  1. 01Sermorelin is a useful tool for diagnosing growth hormone deficiency, with fewer false positives compared to other tests.
  2. 02Daily use of sermorelin showed significant increases in height velocity in many children over a 12-month period.
  3. 03The long-term effects of sermorelin on final adult height are still being studied.
PubMed
#05

Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.

Otin Joanie, et al. · Electrophoresis · 2023

In VitroInfluence1.0
10
Researchers observed that a capillary electrophoresis method successfully separated enantiomeric GHRH analogs, including sermorelin, enhancing detection sensitivity for doping analysis.

Key findings

  1. 01The method allowed for the first-time separation of enantiomeric GHRH analogs, which differ by the chirality of one amino acid.
  2. 02A significant increase in detection sensitivity was achieved using a large volume sample stacking technique.
  3. 03The optimized method successfully detected GHRH analogs in urine with a signal enhancement factor of 640.
PubMed
#06

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Sinha Deepankar K, et al. · Translational andrology and urology · 2020

Review
9
The review highlighted that growth hormone secretagogues, including sermorelin, may improve body composition and alleviate symptoms in hypogonadal males, although clinical efficacy data remains limited.

Key findings

  1. 01Researchers observed that male hypogonadism is linked to obesity and metabolic syndrome, affecting overall health.
  2. 02The review highlighted that growth hormone secretagogues, like sermorelin and ibutamoren, could improve body composition and reduce symptoms of hypogonadism.
  3. 03However, the current lack of extensive clinical data limits understanding of how GHS can be effectively integrated into treatment for hypogonadal men.
0.5 mg/kg per daysubcutaneous(rat)12 weeks4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutesintravenous(human)not mentioned0.03-mg/kgintravenous(human)up to 7 days100 microg/kgsubcutaneous(rat)3 months0.01-1 mg/kgintravenous(rat)not mentioned5 or 30 µgnot mentioned(fish)21 days50 nmol/kgnot mentioned(pig)not mentioned2.7 mg/kgoral(dog)not mentioned
PubMed
#07

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

Human
3
The study demonstrated that GHRP/SERM therapy significantly increased serum IGF-1 levels in hypogonadal men, with a mean posttreatment level of 239.0 ng/mL.
PubMed
#08

In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.

González-López Nicolás Mateo, et al. · Biomedical chromatography : BMC · 2023

In Vitro
2
The study established that certain peptides, including sermorelin, exhibit stability in biological matrices, making them suitable as internal standards for peptide quantification.

Key findings

  1. 01Researchers observed that the matrix effect and sample pretreatment significantly influence peptide recovery in biological samples.
  2. 02GHRP-4, GHRP-6, and Sermorelin (22-29) were identified as stable internal standards for quantifying peptides.
  3. 03The study established a unique profile for each peptide regarding its stability and protein binding.
120 microg/kgintraperitoneally(rat)300 nmol/kg(mouse)9 weeks6 mg/kgintravenously(growing pig)seven days3 and 30 microg/kg(rat)90 microgramsi.v.(human)1 microg/kgi.v.(human)2 microg/kgi.v.(human)1 microgram/kgi.v.(human)
PubMed
Safety

Safety & Handling

Research Gaps

No randomized controlled human trials have been published specifically examining the clinical efficacy of sermorelin and other growth hormone secretagogues in the management of hypogonadism. Additionally, the long-term effects of sermorelin on body composition and metabolic health in diverse populations remain unclear, as well as the detailed mechanisms by which it influences IGF-1 signaling and satellite cell repair in human subjects.

Solubility

Sermorelin is soluble in water and aqueous buffers.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not a controlled substance.

🇦🇺AU

Not approved by the TGA as a medicinal product.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

18 total
1
90
1
99
1
03
1
15
2
16
1
17
2
20
1
21
2
22
3
23
1
24
1
25
1
26
Pricing

Price Comparison

  • BESTPeptide CraftersUS
    10mg
    $55.00
    Price/mg
    $5.50/mg
    View
  • Welli LabsUS
    10mg
    $54.99
    Price/mg
    $5.50/mg
    View
  • Peptide CraftersUS
    5mg
    $30.00
    Price/mg
    $6.00/mg
    View
  • Glacier AminosUS
    10mg
    $62.99
    Price/mg
    $6.30/mg
    View
  • RCpeptidesEU
    10mg
    $64.80
    Price/mg
    $6.48/mg
    View

Top 5 of 38 offers from 38 vendors. Prices updated daily.

See all Sermorelin prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Sermorelin

Serum Level Visualizer

Visualize Sermorelin serum levels over time

Mechanism

Related Peptides

GHRP-2TesamorelinMK-677GHRP-6IpamorelinCJC-1295

Track Sermorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer